Related Experiment Video

Updated: Feb 21, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling

Xiaofan Yang1, Yufeng Ding2, Miao Xiao2

  • 1Department of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Chemico-Biological Interactions
|October 9, 2017
PubMed

Insights

RY10-4 combats multidrug resistance (MDR) in breast cancer by downregulating P-glycoprotein (P-gp) and inhibiting the PI3K/Akt/NF-κB pathway. This combined therapy enhances sensitivity to adriamycin (ADR), showing significant in vivo tumor suppression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) in cancer limits chemotherapy efficacy.
  • P-glycoprotein (P-gp) overexpression is a key mechanism mediating MDR.
  • The PI3K/Akt/NF-κB pathway is implicated in MDR development.

Purpose of the Study:

  • To investigate the effect of RY10-4 on adriamycin (ADR)-resistant breast cancer cells (MCF-7/ADR).
  • To determine if RY10-4 can reverse MDR by targeting P-gp and the PI3K/Akt/NF-κB pathway.
  • To evaluate the in vivo efficacy of combined ADR and RY10-4 treatment.

Main Methods:

  • MCF-7/ADR cells were used to model adriamycin resistance.
  • P-gp expression levels were analyzed in response to RY10-4 treatment.
  • The PI3K/Akt/NF-κB signaling pathway was assessed.
  • In vitro and in vivo experiments evaluated the combined effect of ADR and RY10-4.

Main Results:

  • RY10-4 downregulated P-gp expression in MCF-7/ADR cells.
  • RY10-4 treatment increased chemosensitivity to ADR.
  • RY10-4 suppressed the PI3K/Akt/NF-κB pathway in resistant cells.
  • Combined ADR/RY10-4 treatment showed superior tumor suppression in vivo compared to ADR alone.

Conclusions:

  • RY10-4 effectively reverses the MDR phenotype in MCF-7/ADR cells.
  • Inhibition of the PI3K/Akt/NF-κB pathway by RY10-4 is crucial for MDR reversal.
  • Combined ADR and RY10-4 therapy presents a promising strategy for overcoming MDR in breast cancer.
Keywords:
MCF-7/ADR cellsMultidrug resistanceP-glycoproteinPI3K/Akt/NF-κB pathwayRY10-4

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K